Inhibrx Biosciences, Inc. · NASDAQ:INBX
Inhibrx Biosciences — Investor Presentation (August 2024)
25 slides from Inhibrx Biosciences's investor presentation, Aug 13, 2024
Slide 1: Inhibrx Investor Presentation
INHIBRX Investor Presentation Innovation Driven Outcomes Focused
Slide 2: Presentation disclaimer
2 Presentation disclaimer This presentation of Inhibrx Biosciences, Inc. (the “Company”) contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “o
Slide 3: Our company
3 Our company To discover & develop effective biologic treatments for people with life-threatening conditions We aim to evolve into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following: Rapidly advance and optimize clinical
Slide 4: Our company: expertise and snapshot
4 Our company In-house expertise: 160+ employees with an experienced leadership team >300 ozekibart (INBRX-109) Patients treated to date Discovery Protein engineering Cell biology Translational research Chemistry Manufacturing and controls Clinical development and operations Company snapshot: founde
Slide 5: Inhibrx's innovative approach to therapeutic discovery
5 Inhibrx’s innovative approach to therapeutic discovery Our core belief: Our technology and protein engineering expertise enables us to efficiently identify optimal therapeutic formats bespoke to the target biology. Therapeutics tailored to disease biologyRapid and iterative optimization processMod
Slide 6: Clinical Pipeline
6 Clinical Pipeline ozekibart (INBRX-109) tetravalent DR5 agonist INBRX-106 hexavalent OX40 agonist + Precisely engineered valency to mediate optimal balance of efficacy and safety. + Registration-enabling study in chondrosarcoma underway. + Expansion of Ewing cohort following preliminary efficacy d
Slide 7: ozekibart (INBRX-109) tetravalent DR5 agonist
ozekibart (INBRX-109) tetravalent DR5 agonist Previous generation Goal: To develop a more precise DR5 agonist able to selectively induce apoptosis in tumor cells Empirically selected tetravalent DR5 agonist that restricts unwanted secondary clustering DR5 agonists with limited on target effect or un
Slide 8: ozekibart: a next generation DR5 agonist
8 INBRX-109 ozekibart (INBRX-109): a next generation DR5 agonist with an optimized balance of efficacy and safety Death Receptor 5 (DR5 / TRAIL-R2) is highly expressed on tumorigenic, transformed or damaged cells but not normal cells, making DR5 a promising therapeutic target in oncology1-4 ozekibar
Slide 9: ozekibart: Phase 1 trial design
9 INBRX-109 ozekibart (INBRX-109): Phase 1 trial design N=20 N=116 Dose expansion with chemotherapy N=130 Part 3 Completed Completed Part 2 ozekibart (INBRX-109) single-agent dose expansion ozekibart (INBRX-109) single-agent dose escalation Part 1 Study of ozekibart (INBRX-109) in patients with loca
Slide 10: Encouraging mPFS and clinical responses in chondrosarcoma
10 INBRX-109 Encouraging mPFS and clinical responses observed in Chondrosarcoma patients treated with ozekibart (INBRX-109) Impact of valency on DR5-mediated cell death IDHmt, isocitrate dehydrogenase 1/2 mutant; PFS, progression-free survival. a Includes 1 patient from dose-escalation cohort A4 (IN
Slide 11: ozekibart Phase 3 registration enabling study in chondrosarcoma
11 INBRX-109 ozekibart (INBRX-109) Phase 2 registration enabling study in chondrosarcoma + FDA fast track designation and orphan-drug designation + EMA orphan-drug designation Patients: R 2:1 Conventional chondrosarcoma, Grades 2 and 3, unresectable or metastatic. ozekibart (INBRX-109) Placebo 3 mg/
Slide 12: ozekibart in combo with IRI/TMZ in Ewing sarcoma
12 INBRX-109 ozekibart (INBRX-109) in combo with IRI/TMZ in metastatic, unresectable Ewing sarcoma Efficacy Disease control rate was 76.9%, or 10 out of 13 patients as measured by RECISTv1.1. + Most common adverse events (diarrhea, nausea, and fatigue) were consistent with the known safety profile o
Slide 13: INBRX-106 hexavalent OX40 agonist
INBRX-106 hexavalent OX40 agonist Hexavalent OX40 agonist with enhanced clustering/signaling Bivalent OX40 agonists elicit weak downstream signals with limited clinical activity Previous generation Goal: To develop a potent OX40 agonist able to induce robust signal activation weak strong Inhibrx sol
Slide 14: INBRX-106: generating robust OX40 signaling
14 INBRX-106 INBRX-106: generating robust OX40 signaling to drive anti-tumor activity INBRX-106 is designed to boost anti-tumor T-cell activity by potently activating the OX40 co-stimulatory pathway Six OX40 sdAbs IgG Fc Hexavalent Simultaneously engage multiple OX40 to drive enhanced clustering/sig
Slide 15: INBRX-106 study design
15 INBRX-106 INBRX-106 study design ClinicalTrials.gov identifier, NCT04198766. Protocol version 7.0; March 5, 2024. a Chemo will be administered during the first 4 cycles. Pemetrexed can be continued after 4 cycles until progression or up to 35 cycles. Chemo, chemotherapy; CPI, checkpoint inhibitor
Slide 16: INBRX-106 + pembro clinical activity in HNSCC
16 INBRX-106 INBRX-106 + pembro demonstrated clinical activity in patients with PD-L1+ CPI-R/R or CPI-naive HNSCC 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 PD-L1 CPS 0 100 0 30 1 10 75 20 100 100 10 5 24 90 25 -60 20 -100 -80 -40 -20 0 40 Be st c ha ng e fr om b as el in e, % Cohort CPI-naïve (F4) CPI-R/R
Slide 17: INBRX-106 + pembro clinical activity in NSCLC
17 INBRX-106 INBRX-106 + pembro demonstrated clinical activity in patients with PD-L1+ CPI-R/R NSCLC 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 19 20 21 22 23 24 25 26 PD-L1 TPS 60 20 95 10 80 80 90 2 11 20 3 75 10 10 35 1 50 1 1 10 41 100 50 60 100 90 Data cutoff: August 1, 2024. Preliminary data
Slide 18: Seamless Phase 2/3 study of INBRX-106 in HNSCC
18 INBRX-106 Seamless Phase 2/3 study of the hexavalent OX40 agonist INBRX-106 with pembrolizumab in 1L R/M HNSCC with PD-L1 CPS ≥20 ClinicalTrials.gov identifier, NCT06295731. Protocol version 1.0; January 31, 2024. INBRX-106 to be administered every 3 weeks. Pembro 200 mg to be administered every
Slide 19: Investor Relations
Investor Relations: KELLY DECK, CPA CFO 11025 N. Torrey Pines Road Suite 140 La Jolla, CA 92037 858.795.4260 ir@inhibrx.com
Slide 20: Appendix
Appendix 2 mill
Slide 21: ozekibart is a potent inducer of extrinsic cell death via DR5
21 INBRX-109 ozekibart (INBRX-109) is a potent inducer of extrinsic cell death via the DR5 pathway Ozekibart (INBRX-109), a tetravalent DR5 agonist, is designed to simultaneously engage four DR5 molecules to drive enhanced clustering/signaling in tumor cells while minimizing off-target effects Apopt
Slide 22: ozekibart is precision-engineered for optimal potency and safety
22 INBRX-109 ozekibart (INBRX-109) is precision-engineered for optimal potency and safety Ab (nM) 100 InSphero 3D inSightTM human liver microtissue model: 75 50 25 1 10 100 Impact of valency on cell death: Impact of valency on DR5-mediated cell death ozekibart (INBRX-109) tetravalent Hexavalent DR5
Slide 23: INBRX-106: mechanism of action
23 INBRX-106 INBRX-106: mechanism of action The T-Cell Receptor (TCR) recognizes a tumor-associated antigen presented via MHC. In response, OX40 is upregulated on tumor reactive TILs facilitating an immune response directed towards the tumor. Effective OX40 agonism potentiates the body’s immune resp
Slide 24: Higher OX40 valency drives superior T cell activation
24 INBRX-106 Higher OX40 valency drives superior T cell activation and reduces Treg suppression Hexavalent INBRX-106 engagement drives superior co-stimulation of both CD4 and CD8 T-cells versus bi-valent OX40 mAbs INBRX-106, but a not bivalent OX40 mAb, reduces regulatory T-cell (Treg) mediated supp
Slide 25: Valency drives OX40 agonism in CPI-resistant tumor models
25 INBRX-106 Valency drives OX40 agonism in CPI-resistant tumor models Syngeneic B16F10 Mouse Tumor Model OX40 agonism upregulates PD-L1 expression on CD4 and CD8 T-cells supporting rationale of combination with anti-PD1 agents Hexavalent INBRX-106-a* demonstrated single-agent, single-dose activity
Inhibrx Biosciences — Investor Presentation (August 2024) on 6ix